Thus, these results represent a strong rationale for follow-up studies addressing combination therapies of Danusertib with IM and potentially, 2nd generation tyrosine kinase inhibitors such as Nilotinib, Dasatinib and Bosutinib in order to improve therapeutic effects in BCR-ABL-positive leukemias. The gene discussed is ABL1; the disease is leukemia.